The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.
Click on the button below to create your account and get immediate access to thousands of articles.
BioNTech and CureVac take vaccine patent dispute to court
German pharmaceutical company BioNTech has filed a lawsuit before the Federal Patent Court in a dispute with CureVac regarding Covid-19 vaccines, the court announced in Munich.
January13,2023
German vaccine developer BioNTech posts 30% turnover hike in H1
German pharmaceutical company BioNTech - which partnered with US giant Pfizer to bring one of the world's first coronavirus vaccines to market - increased its turnover in the first half of the year by 30.1% to €9.57 billion ($9.74 billion) compared to the first half of 2021.
August10,2022
BioNTech expects Omicron variant vaccines results within weeks
Results of clinical studies looking at whether BioNTech vaccines repurposed to combat Omicron variants of the coronavirus are effective and safe are expected "in the coming weeks," the German company said.
June07,2022
Germany's BioNTech posts billion-euro profit in first quarter
German vaccine pioneer BioNTech posted a net profit of 1.13 billion euros (1.37 billion dollars) in the first quarter, as demand for its Covid-19 jab continued to grow worldwide.
May17,2021
250 million dollars for BioNTech -- COVID-19 vaccine data expected soon
The Mainz-based biopharmaceutical company BioNTech is raising fresh capital through an investment by Singapore's sovereign wealth fund Temasek. In total, a private placement of shares with Temasek and other investors would bring in 250 million US dollars, BioNTech announced in Mainz on Monday.
July02,2020
If you have any questions, please enter them in the box below.
Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.
Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.
